Pricing Log in Create free account
Saturday 7 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−16.4%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.65 0.05 −0.05%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by regions Fiscal 2025

  • United States
  • Rest of world

Every year since 2013 →

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 3.52%

Capital & Financial Ratios $m

Size
Market Cap 6,580.00
Revenue ttm 1,562.21
Net income ttm 269.91
Free cash flow ttm 393.09
Net debt Q (111.87)
Valuation
P/E 24.30
Forward P/E 21.30
Price / sales 4.21
Forward P/S Powerpack
Price / FCF 16.72
Price / book 5.01
Financial health
Current ratio Q 3.25 (at or above 1.5: strong)
Debt / equity Q 0.42 (at or below 0.5: strong)
Interest coverage Q 6.52
Growth
Revenue growth Q +1.54% (above 0%: growing)
Operating income growth Q −26.16% (below 0%: shrinking)
EPS, this year −10.77% (below 0%: weak)
EPS, next year A +20.30% (at or above 15%: strong)
Revenue, next year A −4.39% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +10.03%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.1×, against a ten-year median of 3.2×; over the ten years it ranged from 1.3× in 2016 to 8.7× in 2022.
P/E against its own 10 years 69.48%
10-year low 10-year high
P/S against its own 10 years 72.69%
10-year low 10-year high
P/B against its own 10 years 39.15%
10-year low 10-year high
EV/Sales against its own 10 years 69.83%
10-year low 10-year high
EV/FCF against its own 10 years 38.82%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 714 913 359 684
Receivables 284 329 374 346
Inventory 64 68 65 64
Other 24 16 102 30
1,086 1,327 900 1,124
2023 2024 2025 Q'26
Payables 41 35 43 48
ST’ Debt 1 1 1 1
Other — — 22 —
187 241 333 346

Compound Annual Growth %

10y 5y 3y
Sales 18.04% 35.35% 18.13%
Cash Flow 33.46% 88.49% 11.46%
Earnings 0.00% 0.00% 102.64%
Book Value 0.00% 16.21% 34.58%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 1.33 Actual 1.55

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 1.27 1.27 Met by 0.00
Q4 FY25 1.18 1.67 Beat by 0.49
Q1 FY26 1.25 1.46 Beat by 0.21
Q2 FY26 1.33 1.55 Beat by 0.22
Q3 FY26 1.24 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 1.80 1.11 0.33 — —
’25 1.02 1.12 0.41 0.82 3.41
’24 1.87 0.88 1.79 (0.17) 4.36
’23 (0.04) 1.33 1.88 1.47 4.65
’22 0.61 0.61 0.86 (1.74) 0.40
’21 0.13 (0.39) (0.20) (0.59) (1.06)
’20 0.08 (0.16) (0.10) (0.05) (0.25)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 377 388 390 — —
’25 373 378 384 407 1,542
’24 370 394 379 391 1,534
’23 301 322 320 354 1,296
’22 209 224 239 263 935
’21 93 101 102 130 425
’20 91 66 89 94 339
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 125 92 102 — —
’25 108 87 105 90 390
’24 127 85 175 158 545
’23 109 (32) 117 112 305
’22 10 73 94 105 282
’21 10 26 4 14 54
’20 9 (2) 9 1 16
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 127 90 95 — —
’25 99 79 95 81 354
’24 99 74 159 151 483
’23 99 (43) 200 100 357
’22 9 68 87 101 265
’21 23 23 2 9 58
’20 7 (4) 5 (3) 4
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 6.3% a year for ten years. It grew 31.6% a year over the last ten.

Implied
6.3%
10 years, reported
31.6%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

2.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 302 331 343 347 339 425 935 1,296 1,534 1,542 1,562 +19.9% 1,474 1,654 1,878 +6.8%
Gross margin, % 45.64 48.93 50.93 50.33 40.88 44.14 62.21 54.73 64.43 61.10 61.26 +15.5 pt
EBT 28 40 50 29 (11) (75) 27 411 431 314 342 +30.6%
EBT margin, % 9.37 11.96 14.43 8.24 (3.38) (17.65) 2.86 31.70 28.10 20.35 21.92 +11.0 pt
Net income 27 123 41 32 (13) (71) 28 327 312 234 270 +27.2%
Per share, $
Per share, $ Revenue 9.42 8.89 8.98 8.91 6.27 6.30 13.65 18.99 22.17 22.84 23.92 +10.3%
Earnings 0.84 3.31 1.06 0.81 (0.25) (1.06) 0.41 4.79 4.52 3.46 4.14 +17.0%
Cash flow 1.55 1.47 1.60 2.06 0.30 0.80 4.11 4.47 7.87 5.78 6.27 +15.8%
Capex 0.10 (0.44) (0.50) (0.57) (0.23) 0.05 (0.24) 0.75 (0.89) (0.53) (0.25) n/m
Free cash flow 1.65 1.03 1.10 1.50 0.07 0.85 3.87 5.22 6.98 5.25 6.02 +13.7%
Book value (3.32) 0.62 1.86 2.94 9.50 6.88 6.53 11.95 15.72 16.15 20.76 n/m
Shares, m 32 37 38 39 54 67 68 68 69 67 66 +8.6%
Valuation, ×
Valuation, × P/E 10.41 6.38 14.76 25.32 0.00 0.00 123.59 13.20 19.79 19.35 24.30 23.3
P/S 0.94 2.36 1.74 2.30 2.15 4.59 3.71 3.32 4.04 2.91 4.21 2.8
P/B 0.00 33.61 8.43 6.98 1.42 4.20 7.76 5.28 5.69 4.12 5.01 7.7
EV/Sales 1.69 2.94 2.19 2.59 2.56 4.76 3.86 3.21 3.81 3.05 4.14 3.1
EV/FCF 9.66 25.34 17.86 15.44 221.58 35.17 13.62 11.66 12.10 13.28 16.43 37.6
Cash, $m
Cash, $m Operating cash flow 50 55 61 80 16 54 282 305 545 390 409 +25.7%
Capex 3 (16) (19) (22) (12) 4 (17) 51 (62) (36) (16) n/m
Free cash flow 53 38 42 58 4 58 265 357 483 354 393 +23.5%
Balance, $m
Balance, $m Working capital 67 101 143 107 104 145 430 898 1,086 567 778 +26.8%
Net debt 227 192 153 101 139 76 142 (151) (347) 210 (112) (0.8%)
Shareholders’ equity (107) 23 71 115 514 464 447 816 1,088 1,090 1,356 n/m
Returns, %
Returns, % ROA 10.74 38.57 9.84 7.49 (2.11) (8.22) 2.57 21.98 17.21 11.10 11.41 +0.4 pt
ROIC 29.37 15.06 17.99 14.97 (0.40) (7.03) 3.84 34.28 38.52 14.94 14.62 (14.4) pt
ROE (18.34) (296.51) 85.94 34.12 (4.29) (14.57) 6.16 51.73 32.82 21.45 21.81 +39.8 pt
People
People Employees 465 483 488 508 595 612 698 834 808 1,193 — +11.0%
Revenue/emp, $m 0.65 0.69 0.70 0.68 0.57 0.69 1.34 1.55 1.90 1.29 — +7.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Business profile

Updated

Lantheus Holdings is a healthcare company focused on radiopharmaceuticals: products that use radioactive material to help clinicians see or treat disease. Its commercial portfolio is primarily diagnostic, helping clinicians examine patients for cancer, heart conditions and signs associated with Alzheimer’s disease. The company is headquartered in Massachusetts, and Mary Anne Heino is its chief executive officer while the board searches for a successor.

Its prostate cancer imaging agent PYLARIFY is used with PET scans to locate certain cancer lesions. Neuraceq is a PET imaging agent used to estimate the density of amyloid plaques in the brains of adults being evaluated for Alzheimer’s disease or other causes of cognitive decline. DEFINITY is different: it is an injectable ultrasound-enhancing agent used to improve heart images when an echocardiogram is otherwise difficult to interpret.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by regions, and margins
United States 1,459 94.63%
Rest of world 83 5.37%
Gross margin 61.10%
Operating margin 20.16%
Pre-tax margin 20.35%

Revenue by segment since 2013

Lantheus Holdings, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RDY Dr. Reddy's Laboratories Ltd $12.1B 45.4× 30.7× −10.09% (below 0%: shrinking) −36.84% (below 0%: shrinking) −70.49% (below 0%: shrinking) 52.13% 14.63% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 161× +11.26% (above 0%: growing) n/m +22.83% (above 0%: growing) 56.92% 0.00% Compare
ALKS Alkermes plc $7.5B — (loss-making) — (loss-making) +21.80% (above 0%: growing) −80.60% (below 0%: shrinking) +6.78% (above 0%: growing) 80.38% 7.50% Compare
KNSA Kiniksa Pharmaceuticals International, plc $6.9B 65.9× 67.8× +58.12% (above 0%: growing) +142.20% (above 0%: growing) +43.51% (above 0%: growing) 90.29% 18.97% Compare
AMRX AMNEAL PHARMACEUTICALS, INC. $6.8B 38.2× 44.2× +9.96% (above 0%: growing) +267.00% (above 0%: growing) −50.92% (below 0%: shrinking) 38.73% 11.06% Compare
LNTH Lantheus Holdings, Inc. $6.6B 24.3× 21.3× +1.54% (above 0%: growing) −16.44% (below 0%: shrinking) +7.71% (above 0%: growing) 62.43% 8.26%
HIMS Hims & Hers Health, Inc. $5.6B — (loss-making) — (loss-making) +38.25% (above 0%: growing) n/m +5.09% (above 0%: growing) 63.83% (12.90%) Compare
SUPN Indivior Pharmaceuticals Inc. $5.6B 7.0× 9.5× +13.38% (above 0%: growing) +241.47% (above 0%: growing) +240.68% (above 0%: growing) 85.67% 50.84% Compare
LQDA Liquidia Corporation $4.0B 28.4× 22.1× +1,842.73% (above 0%: growing) n/m +270.23% (above 0%: growing) 93.27% 49.81% Compare
Median of peers $6.9B 38.2× 37.5× +17.59% +142.20% +14.81% 72.11% 12.85%

All 84 Drug Manufacturers Specialty & Generic stocks →

From the latest earnings call

Updated

  • On the Q1 call, Mary Ann Haino said Lantheus planned to transition PYLARIFY customers to TruVu geographically, with coverage and payment arrangements in place before orders begin.
  • CFO Bob Marshall said on the Q1 call that he expected modest PYLARIFY volume growth while monitoring competition and pricing.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 116.41%
Held by the ten largest 62.19%
Holder Shares Stake Change
BlackRock 8.40m 12.87% +214.45k
Vanguard 6.75m 10.34% +73.99k
FARALLON CAPITAL MANAGEMENT, L.L.C. 5.58m 8.56% 0.00
Jupiter Topco 5.19m 7.95% +5.19m
Fidelity (FMR) 3.88m 5.94% −746.48k
American Century 2.82m 4.32% +1.04m
State Street 2.50m 3.83% +70.89k
T. Rowe Price 1.90m 2.92% +983.62k
Geode Capital Management 1.84m 2.82% +75.42k
Morgan Stanley 1.73m 2.65% +79.84k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 20 March 2026

Ownership

Directors and executive officers, together 1.70%
BlackRock, Inc. 13.30%
The Vanguard Group, Inc. 10.80%
Janus Henderson Group PLC 8.80%
Entities affiliated with Farallon Partners, L.L.C. 8.40%
FMR LLC 6.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lantheus Holdings, Inc. (LNTH) Latest News

5 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · Associated Press

12 Oct

Impact 3 · · StockStory

30 Sep

Impact 4 · · GlobeNewswire

28 Sep

Impact 4 · · GlobeNewswire

26 Sep

Impact 3 · · Simply Wall St.

25 Sep

Impact 4 · · Simply Wall St.

23 Sep

Impact 4 ·
Impact 3 · · StockStory

22 Sep

Impact 4 · · GlobeNewswire

26 Aug

Impact 5 · · pitchbook.com

14 Aug

Impact 4 ·

6 Aug

Impact 4 ·
Impact 4 ·

4 Aug

Impact 4 ·

3 Aug

Impact 5 ·
Impact 5 ·

27 Jul

Impact 4 · · Stocktwits

26 Jun

Impact 4 ·

2 Jun

Impact 3 · · GlobeNewswire

22 May

Impact 4 · · Simply Wall St.

21 May

Impact 3 · · GlobeNewswire

14 May

Impact 3 ·

11 May

Impact 4 · · Simply Wall St.

8 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Zacks Small Cap Research
Impact 4 · · Simply Wall St.
Impact 4 · · MarketBeat

7 May

Impact 4 · · StockStory
Impact 4 · · GlobeNewswire

LNTH metrics, ten years each

stockrow.com/LNTH · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com